S&P 500 cuts losses as Nvidia climbs ahead of results
Investing.com -- Sotera Health Company (NASDAQ:SHC) reported first-quarter 2025 results that surpassed analyst expectations, sending its shares up 4.6% in trading. The global provider of sterilization solutions and lab testing services posted adjusted earnings per share of $0.14, beating the consensus estimate of $0.12, while revenue of $255 million topped expectations of $245.13 million.
The company’s net revenues increased 2.6% YoY to $255 million, or 4.4% on a constant currency basis. Adjusted EBITDA rose 8.8% to $122 million compared to the same quarter last year, representing an 11.2% increase on a constant currency basis.
Despite reporting a net loss of $13 million or -$0.05 per diluted share, which included a $31 million settlement related to ethylene oxide claims, Sotera Health’s adjusted figures showed improvement. The company reaffirmed its full-year 2025 outlook, projecting net revenue growth of 4.0% to 6.0% and adjusted EBITDA growth of 4.5% to 6.5%, both on a constant currency basis.
Chairman and CEO Michael B. Petras, Jr. commented, "We are pleased to report a solid start to the year with mid-single digit revenue growth and strong double digit Adjusted EBITDA growth, on a constant currency basis."
The company’s Sterigenics segment saw a 1.9% increase in net revenues to $170 million, while Nordion reported a significant 35.6% jump to $33 million. However, Nelson Labs experienced a 9.3% decline to $52 million.
Sotera Health maintains its full-year 2025 adjusted EPS guidance of $0.70 to $0.76, in line with the analyst consensus of $0.74.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.